positive
48 days agoMedline files for U.S. IPO targeting up to $50 billion valuation
Medline Industries has publicly filed for a U.S. initial public offering that could value the medical‐supplies giant at up to $50 billion. The company reported revenue of $13.53 billion in the first half of 2025—a 9.7% increase—alongside a profit of $655 million. Backed by private‐equity firms Blackstone, Carlyle Group and Hellman & Friedman, Medline’s listing is being seen as a key test of investor appetite across large U.S. IPOs after years of dormancy.
Tags:
- ipo
- markets
Reuters• By Sneha Pathak
Explore:High Return Equity Mutual Fund
positive
48 days agoMedline files for U.S. IPO targeting up to $50 billion valuation
Medline Industries has publicly filed for a U.S. initial public offering that could value the medical‐supplies giant at up to $50 billion. The company reported revenue of $13.53 billion in the first half of 2025—a 9.7% increase—alongside a profit of $655 million. Backed by private‐equity firms Blackstone, Carlyle Group and Hellman & Friedman, Medline’s listing is being seen as a key test of investor appetite across large U.S. IPOs after years of dormancy.
Tags:
- ipo
- markets
Reuters• By Sneha Pathak
Explore:High Return Equity Mutual Fund
Recently
1 min read
73 words
Medline files for IPO with up to $50 billion valuation as investor appetite returns to major U.S. listings.
Medline Industries has publicly filed for a U.S. initial public offering that could value the medical‐supplies giant at up to $50 billion. The company reported revenue of $13.53 billion in the first half of 2025—a 9.7% increase—alongside a profit of $655 million. Backed by private‐equity firms Blackstone, Carlyle Group and Hellman & Friedman, Medline’s listing is being seen as a key test of investor appetite across large U.S. IPOs after years of dormancy.
Medline Industries has publicly filed for a U.S. initial public offering that could value the medical‐supplies giant at up to $50 billion. The company reported revenue of $13.53 billion in the first half of 2025—a 9.7% increase—alongside a profit of $655 million. Backed by private‐equity firms Blackstone, Carlyle Group and Hellman & Friedman, Medline’s listing is being seen as a key test of investor appetite across large U.S. IPOs after years of dormancy.
Tags:
- ipo
- markets
- ipo
- markets
- US
- healthcare
- listing
Oct 28, 2025 • 22:55